Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.44 |
| ▸ | NSD2 | O96028 | 1/20 | 0.44 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 2/20 | 0.42 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31731787 | 0.89 | GRM5 (0.45) | GRM5CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL23922807 | 0.83 | GRM5 (0.51) | GRM5CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL465791 | 0.82 | CHRM2 (0.47) | CHRM2CHRM4CHRM1CHRM3TBK1 | |
| SCHEMBL949354 | 0.82 | CHRM2 (0.47) | CHRM2CHRM4CHRM1CHRM3KDM4E | |
| SCHEMBL16061780 | 0.82 | FAAH (0.58) | CHRM2CHRM4CHRM1CHRM3KDM4E | |
| SCHEMBL25282066 | 0.81 | CHRM4 (0.46) | CHRM2CHRM4CHRM1CHRM3TBK1 | |
| SCHEMBL22769224 | 0.81 | CHRM2 (0.46) | GRM5CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL22166944 | 0.80 | ACHE (0.48) | CHRM2CHRM4CHRM1CHRM3KDM4E | |
| SCHEMBL2137893 | 0.77 | ALDH1A1 (0.68) | CHRM2CHRM4CHRM1CHRM3GPR119 | |
| SCHEMBL617183 | 0.76 | FAAH (0.47) | CHRM2CHRM4CHRM1CHRM3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10696694-B2 | Lanthanide complexes for crystallising biological macromolecules and determining the crystallographic structure thereof | ECOLE NORMALE SUPERIEURE LE LYON (FR) | 2020-06-30 | — | — | US | disclosed |
| WO-2017103545-A1 | LANTHANIDE COMPLEXES FOR CRYSTALLISING BIOLOGICAL MACROMOLECULES AND DETERMINING THE CRYSTALLOGRAPHIC STRUCTURE THEREOF | ECOLE NORMALE SUPERIEURE DE LYON (FR) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696694-B2 | Lanthanide complexes for crystallising biological macromolecules and determining the crystallographic structure thereof | SSB, F12, LGALS1 | GRM5 4292/4885CHRM2 2088/4885CHRM4 1761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.